A Study to Determine the Safety and Effectiveness of a Connective Tissue Allograft (ActiveMatrix) Verses Standard of Care in Adhesive Capsulitis of the Shoulder

The University of Texas System (UT)

Status and phase: Completed; Phase 4

Conditions: Adhesive Capsulitis

Treatments: Drug: Corticosteroid; Drug: Lidocaine; Other: ActiveMatrix

Study type: Interventional

Funder types: Other; Industry

Identifiers

NCT05844930

HSC-MS-21-0706

Details and patient eligibility

About

The purpose of this study is to compare ActiveMatrix® to standard of care corticosteroid injection in the treatment of adhesive capsulitis of the shoulder (frozen shoulder).

Enrollment: 56 patients

Sex: All

Ages: 18 to 75 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Provision of signed and dated informed consent form
• Stated willingness to comply with all study procedures and availability for the duration of the study
• Have a clinical diagnosis of adhesive capsulitis, defined as: i. pain along the C5 dermatome; and ii. limitations of passive range of motion of more than 20 degrees in the abduction internal rotation, neutral external rotation, forward elevation and abduction planes when compared to the contralateral shoulder
• Have no contraindications or allergies to the treatment administered
• Have experienced shoulder pain for more than 6 weeks and less than 1 year (to ensure the patient is in the "freezing" stage of adhesive capsulitis).
• Have current imaging studies (plain radiographs and MRI exams) of the shoulder to rule out other etiologic diagnoses.

Exclusion criteria

• Any prior treatment for this episode of shoulder pain, such as prior intra-articular injection or prior physiotherapy
• Evidence, based on MRI or plain radiographs, of any pathology within the shoulder other than adhesive capsulitis (e.g., glenohumeral osteoarthritis, full thickness tears of the labrum or rotator cuff, tendinosis, calcific tendonitis)
• A history of significant trauma to the shoulder
• Poorly controlled diabetes mellitus, as defined by HbA1c > 7.5 mmol/L and glucose > 200 mg/dL. For diabetic participants HbA1c and glucose levels will be measured prior to intervention and documented for later analysis. For non-diabetic participants, previous labs will be utilized. All other medical diseases will be documented for later analysis.
• History of Cardiovascular Accident (CVA) such as stroke or Transient Ischemic Attack (TIA)
• Blood dyscrasias
• Use of any NSAIDs besides Tylenol. A letter will be sent to each participant's primary care physician(s) requesting that no additional pain medications be given for the duration of the study
• Prior shoulder surgery

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Quadruple Blind

---

56 participants in 2 patient groups

Intra-articular Injection of Corticosteroid Plus Lidocaine

Active Comparator group

Description:

Participants will receive a corticosteroid injection consisting of Triamcinolone 20 mg (1cc) with Lidocaine 10 mg/ml (5 cc).

Treatment:

Drug: Lidocaine

Drug: Corticosteroid

Intra-articular Injection of ActiveMatrix Plus Lidocaine

Experimental group

Description:

Participants will receive an injection consisting of ActiveMatrix (1cc; Skye Biologics, Inc.) with Lidocaine 10 mg/ml (5cc).

Treatment:

Other: ActiveMatrix

Drug: Lidocaine